Detalhe da pesquisa
1.
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Blood
; 118(18): 4882-9, 2011 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21725056
2.
O2â - and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
Cancer Cell
; 31(4): 487-500.e8, 2017 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28366679
3.
O2â - and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
Cancer Cell
; 32(2): 268, 2017 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28810149